MedTrace Logo

A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology

NCT02512757 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2018-02-28

No results posted yet for this study

Summary

This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk for developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy and histopathology.

Conditions

Sponsors & Collaborators

  • Ajinomoto Co., Inc.

    collaborator INDUSTRY

  • Innovis LLC

    lead INDUSTRY

Principal Investigators

  • Gregg S. Britt · Innovis LLC

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-08-13
Primary Completion
2017-07-17
Completion
2017-07-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02512757 on ClinicalTrials.gov